NuvinkaDx Announces Major Milestones for Portfolio Companies GeneProof and ALPCO
July 22, 2025 – Salem, NH – NuvinkaDx, a leading innovator in diagnostic solutions, today announced two significant product and regulatory milestones from its operating companies, GeneProof and ALPCO.
“These dual milestones reflect the strength of NuvinkaDx’s diversified diagnostics strategy,” said Erik Allen, CEO of NuvinkaDx. “GeneProof’s expansion into STIs with the myCROBE platform in Europe and ALPCO’s regulatory progress in Canada with KleeYa are both aligned with our global mission to improve clinical outcomes through accessible, high-performance testing solutions.”
“These dual milestones reflect the strength of NuvinkaDx’s diversified diagnostics strategy,” said Erik Allen, CEO of NuvinkaDx. “GeneProof’s expansion into STIs with the myCROBE platform in Europe and ALPCO’s regulatory progress in Canada with KleeYa are both aligned with our global mission to improve clinical outcomes through accessible, high-performance testing solutions.”
Category Press Releases